TMCi named its 2024 Accelerator for Cancer Therapeutics cohort.

For the fourth year, Texas Medical Center Innovation has named its annual cohort of Texas health tech innovators working on promising cancer therapeutics.

TMCi named its 2024 Accelerator for Cancer Therapeutics cohort last week, and the 23 Texas researchers and companies selected will undergo a nine-month program that will provide them with mentorship and programming, as well as open doors to potential investors and strategic partners.

“The ACT program provides a bridge to commercialization in Texas by surrounding innovators with strategic mentorship, milestone development, and a network of resources to move their projects forward,” Emily Reiser, associate director of TMC Innovation, says in a news release. "We are excited to welcome this year's cohort and to continue enabling participants to advance their solutions to treat cancer."

The program has accelerated 76 researchers and companies to date, many of which — like March Biosciences and Mongoose Bio — have gone on to secure $130 million in funding from venture capitalists and grant funding.

“Our program has cultivated a dynamic ecosystem where partners, researchers, and inventors, who have been part of the journey since its inception and received various forms of funding, continue to propel their life-saving products and technologies forward," Ahmed AlRawi, program manager of ACT, says in the release. "Our 2024 cohort represents our most diverse cohort to date, including eight companies led by women entrepreneurs. Additionally, we are particularly proud that the cohort includes a blend of new and recurring organizations that have leveraged this opportunity in the past to extend their work and continue the momentum to build off the successes of our previous years.”

The 2024 participants are:

  • Alexandre Reuben of UT-MD Anderson Cancer Center
  • Betty Kim & Jiang Wen of UT-MD Anderson Cancer Center
  • Bin He of Houston Methodist
  • Daniel Kiss & John Cooke of PeakRNA at Houston Methodist
  • Hongjun Liang of Texas Tech-Lubbock
  • Jacob Goell & Isaac Hilton of Mercator Biosciences at Rice University
  • Jay Hartenbach & Matthew Halpert of Diakonos Oncology Corp.
  • Kathryn O’Donnell of UT-Southwestern
  • Maralice Conacci Sorrell of UT-Southwestern
  • Neeraj Saini of UT-MD Anderson Cancer Center
  • Neil Thapar of Barricade Therapeutics Corp.
  • Nina Keshavarzi of Celine Biotechnologies
  • Raphael G. Ognar & Henri Bayle of NKILT Therapeutics Inc.
  • Richard Austin & Michael Abrahamson of Reglagene Inc.
  • Tim Peterson & Joppe Nieuwenhuis of Bioio Inc.
  • Todd Aguilera & Eslam Elghonaimy of UT-Southwestern
  • Venkata Lokesh Battula of Siddhi Therapeutics Inc. at UT-MD Anderson Cancer Center
  • Weei-Chin Lin & Fang-Tsyr Lin of Baylor College of Medicine
  • Yong Li & Dongxiao Feng of Sotla Therapeutics at Baylor College of Medicine
  • Anil Sood & Zhiqiang An of UT-MD Anderson Cancer Center
  • Narendra Kumar & Jayshree Mishra of Texas A&M-College Station
  • Tao Wang of NightStar Biotechnologies Inc. at UT-Southwestern
  • Jian Hu of UT-MD Anderson Cancer Center
The Texas Medical Center's ACT program is making sure the most-promising cancer research makes it to its life-saving commercialization stage. Photo via tmc.edu

Houston program buoys promising cancer research with live-saving innovation

act-ing now

How do you bring promising cancer research to the masses? TMC Innovation's Accelerator for Cancer Therapeutics was established with that question in mind.

Funded by a $5 million grant from CPRIT, or the Cancer Prevention and Research Institute of Texas, in 2019 and in collaboration with the Gulf Coast Consortia and the University of Texas Medical Branch, the first cohort began their intensive work in 2021. The deadline to join the next cohort is October 13.

Since its inception, ACT has seen the forming of 19 companies — two of which have been awarded CPRIT seed grants, along with four in contention for one this year — as well as $92 million in dilutive funding and $10 million in non-dilutive funding.

“We’ve recruited investigators and companies from the breadth and width of the state of Texas, so all the way from Lubbock to Galveston from Dallas to the Rio Grande Valley,” Ahmed AlRawi, program manager, tells InnovationMap. “We've had an amazing set of investigators who have gone through the program — 56 teams to be precise.”

AlRawi says that the first pillar of the program is education. To that end, the cohort works with entrepreneurs in residence like Michael Torres. Best known as the co-founder of ReCode Therapeutics, Torres says that one of his greatest passions lies in translating science into medicines. ReCode is a genetic medicines company that is currently clinical-stage. It’s raised more than $300 million in the last two years, certainly something to which scientist-entrepreneurs earlier in their careers would aspire.

A longtime resident of Dallas, Torres moved his family to Houston last year, calling it “the place to be for cancer startups in Texas.”

Initially, says Torres, Houston wasn’t on his radar. But thanks to a call from ACT external advisor Dan Hargrove, Torres realized that the city might be a fit for him and his goals.

“I wanted to find a project that I could help support, sort of take my experience as a cofounder and help guide the next great startup within the ecosystem,” he says.

Torres and AlRawi agree that the biggest successes to come out of ACT so far include March Biosciences, a company from the first cohort, which is focused on developing CAR-T cell strategies to help combat hematological cancers; CPRIT fundee, OmniNano Pharmaceuticals, which uses patented nanotechnology to co-deliver a pair of therapeutical agents to solid tumors; and the latest, CrossBridge Bio.

Part of the most recent cohort, Torres has joined Drs. Kyoji Tsuchikama and Zhiqiang An as the last company’s CEO. To that end, he’s partnered with the world-class researchers out of UT Health Houston to build a next-generation antibody drug conjugate company that he believes will produce “better and safer and more effective drugs than what's currently on the market today.”

All the more reason that Torres he’s glad to have moved to Houston at what he calls “a really exciting time.” He’s thankful for the Texas Medical Center and the relationships it fosters. “We're all sort of aligning on creating a sustainable biotech ecosystem,” he says. And the next big cancer fighting company may well emerge from ACT.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

This Houston neighbor is the fastest growing wealthy suburb in America

By The Numbers

The Houston-area city of Fulshear is booming like nowhere else: It's now the No. 1 fast-growing affluent suburb in the country.

Fulshear's No. 1 status was unveiled in a new GoBankingRates' study that ranked the "30 Fastest Growing Wealthy Suburbs in America" for 2025. The report examined population changes from 2018 to 2023 among cities and towns in major U.S. metro areas with populations between 25,000 and 100,000 residents. Median household income, average home value, and a "livability score" were also calculated for each locale.

Fulshear, located 34 miles west of downtown Houston, experienced the most dramatic population increase out of all 30 cities in the report. Though the suburb only has an estimated population of 42,616 residents, that number has skyrocketed 237 percent during the five-year period.

A Fulshear resident's median income is $178,398 annually, and the average value of a home in the city comes out to $521,157, the report additionally found.

Fulshear was the second fastest growing city in America in 2023. The city's growth is further reflected by the number of new apartments that were built in the area in 2024.

Texas is tops
Texas cities took the top three fastest growing U.S. suburbs for 2025, with Dallas-area cities of Celina (No. 2) and Prosper (No. 3) experiencing wildly different (yet still sky high) population changes. Celina's population ballooned 190 percent to 43,317 residents, while Prosper's grew 81 percent to an estimated 41,660 people.

Other Texas cities that earned spots in the report include Flower Mound (No. 19), Southlake (No. 27), University Park (No. 28) and Colleyville (No. 29), all in the Dallas-Fort Worth area.

"The old adage that everything is bigger in Texas is true, considering the number of Lone Star State suburbs that are quickly growing in population and overall wealth," the report's author wrote.

The top 10 fastest growing wealthy suburbs in America are:

  • No. 1 – Fulshear, Texas
  • No. 2 – Celina, Texas
  • No. 3 – Prosper, Texas
  • No. 4 – Erie, Colorado
  • No. 5 – Clarksburg, Maryland
  • No. 6 – Zionsville, Indiana
  • No. 7 – Redmond, Washington
  • No. 8 – Dublin, California
  • No. 9 – Parkland, Florida
  • No. 10 – Eastvale, California
---

This story originally appeared on our sister site CultureMap.com.

Rice research breakthrough paves the way for advanced disease therapies

study up

Bioengineers at Rice University have developed a “new construction kit” for building custom sense-and-respond circuits in human cells, representing a major breakthrough in the field of synthetic biology, which could "revolutionize" autoimmune disease and cancer therapeutics.

In a study published in the journal Science, the team focused on phosphorylation, a cellular process in the body in which a phosphate group is added to a protein, signaling a response. In multicellular organisms, phosphorylation-based signaling can involve a multistage, or a cascading-like effect. Rice’s team set out to show that each cycle in a cascade can be treated as an elementary unit, meaning that they can be reassembled in new configurations to form entirely novel pathways linking cellular inputs and outputs.

Previous research on using phosphorylation-based signaling for therapeutic purposes has focused on re-engineering pathways.

“This opens up the signaling circuit design space dramatically,” Caleb Bashor, assistant professor of bioengineering and biosciences and corresponding author on the study, said in a news release. “It turns out, phosphorylation cycles are not just interconnected but interconnectable … Our design strategy enabled us to engineer synthetic phosphorylation circuits that are not only highly tunable but that can also function in parallel with cells’ own processes without impacting their viability or growth rate.”

Bashor is the deputy director for the Rice Synthetic Biology Institute, which launched last year.

The Rice lab's sense-and-respond cellular circuit design is also innovative because phosphorylation occurs rapidly. Thus, the new circuits could potentially be programmed to respond to physiological events in minutes, compared to other methods, which take hours to activate.

Rice’s team successfully tested the circuits for sensitivity and their ability to respond to external signals, such as inflammatory issues. The researchers then used the framework to engineer a cellular circuit that can detect certain factors, control autoimmune flare-ups and reduce immunotherapy-associated toxicity.

“This work brings us a whole lot closer to being able to build ‘smart cells’ that can detect signs of disease and immediately release customizable treatments in response,” Xiaoyu Yang, a graduate student in the Systems, Synthetic and Physical Biology Ph.D. program at Rice who is the lead author on the study, said in a news release.

Ajo-Franklin, a professor of biosciences, bioengineering, chemical and biomolecular engineering and a Cancer Prevention and Research Institute of Texas Scholar, added “the Bashor lab’s work vaults us forward to a new frontier — controlling mammalian cells’ immediate response to change.”

Greentown Labs names new CEO to lead pioneering climate tech incubator

Transition News

Houston and Boston climate tech incubator Greentown Labs has named Georgina Campbell Flatter as the organization’s incoming CEO.

Flatter will transition to Greentown from her role as co-founder and executive director of TomorrowNow.org, a global nonprofit that studies and connects next-generation weather and climate technologies with communities most affected by climate change.

“We are at a transformational moment in the energy transition, with an unprecedented opportunity to drive solutions in energy production, sustainability, and climate resilience,” Flatter said in a news release. “Greentown Labs is, and has always been, a home for entrepreneurs and a powerhouse of collaboration and innovation.”

Previously, Flatter worked to launch TomorrowNow out of tomorrow.io, a Boston-based AI-powered weather intelligence and satellite technology company. The organization secured millions in climate philanthropy from partners, including the Gates Foundation, which helped deliver cutting-edge climate solutions to millions of African farmers weekly.

Flatter also spent 10 years at the Massachusetts Institute of Technology (MIT), where she was a senior lecturer and led global initiatives at the intersection of technology and social impact. Her research work includes time at Langer Lab and Sun Catalytix, an MIT – ARPA-E-funded spin-out that focused on energy storage solutions inspired by natural photosynthesis. Flatter is also an Acumen Rockefeller Global Food Systems Fellow and was closely involved with Greentown Labs when it was founded in Boston in 2011, according to the release.

“It’s rare to find an individual who has impressive climate and energy expertise along with nonprofit and entrepreneurial leadership—we’re fortunate Georgie brings all of this and more to Greentown Labs,” Bobby Tudor, Greentown Labs Board Chair and Chairman of the Houston Energy Transition Initiative, said in a news release.

Flatter will collaborate with Kevin Dutt, Greentown’s Interim CEO, and also continue to serve on Greentown’s Board of Directors, which was recently announced in December and contributed to a successful $4 million funding round. She’s also slated to speak at CERAWeek next month.

“In this next chapter, I’m excited to build on our entrepreneurial roots and the strength of our ever-growing communities in Boston and Houston,” Flatter added in a news release. “Together, we will unite entrepreneurs, partners, and resources to tackle frontier challenges and scale breakthrough technologies.”

Greentown also named Naheed Malik its new chief financial officer last month. The announcements come after Greentown’s former CEO and president, Kevin Knobloch, announced that he would step down in July 2024 after less than a year in the role.

---

This article originally appeared on our sister site, EnergyCapital.